Spectral AI Completes Proof of Concept for Wound Measurement Technology
October 03 2024 - 8:00AM
Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the
“Company”), an artificial intelligence (AI) company
focused on medical diagnostics for faster and more accurate
treatment decisions in wound care, today announced the completion
of a proof-of-concept module of its wound measurement technology
that calculates the total body surface area (“TBSA”) of a burn.
This technology, which is currently integrated into the Company’s
DeepView® System for burn indication (“DeepView AI®-Burn”),
provides a fast, accurate, and standardized measurement that the
Company believes is a significant improvement over current wound
size measurement technology and can improve patient treatment
decisions.
Burn size estimation is a crucial component of
acute burn management. The speed and accuracy of determining burn
size at the earliest stages of care is critical in making treatment
decisions.
Current wound size measurement methods are
limited in their ability to measure the three wound dimensions of
distance, area and volume. This limitation can cause
miscalculations in accurately sizing the wound and result in
suboptimal treatment decisions.
In contrast, Spectral AI’s proprietary wound
measurement technology utilizes the same image capture produced by
DeepView AI®-Burn that provides an immediate, objective and binary
assessment of a burn wound’s healing trajectory to also deliver
distance, area and volume measurements with sub-millimetric
accuracy without reference to any attendant markers or manually
placed stickers. In seconds, a burn size and depth calculation is
generated to further aid clinicians in determining next step
treatment decisions.
“Our wound measurement technology delivers a
more comprehensive representation of an acute burn injury than
currently used methods, and provides a level of accuracy,
uniformity, and standardization that we believe has been missing
from burn care,” said Peter M. Carlson, Chief Executive Officer.
“We believe that this data can help reduce human error and provide
invaluable clinician support regardless of the care setting. This
technology strengthens our conviction that DeepView AI®-Burn has
the potential to change the standard of care in burn wound
treatment.”
Spectral AI's DeepView® System for burn
indication is designed to distinguish between healing and
non-healing tissue by providing an immediate and binary prediction
of wound healing on Day One that can support clinical
decision-making regarding next step treatment plans.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive
AI company focused on medical diagnostics for faster and more
accurate treatment decisions in wound care, with initial
applications involving patients with burns and diabetic foot
ulcers. The Company is working to revolutionize the management of
wound care by “Seeing the Unknown®” with its DeepView® System. The
DeepView® System is a predictive device that offers clinicians an
objective and immediate assessment of a wound’s healing potential
prior to treatment or other medical intervention. With
algorithm-driven results and a goal to change the current standard
of care, the DeepView® System is expected to provide faster and
more accurate treatment insight towards value care by improving
patient outcomes and reducing healthcare costs. For more
information about the DeepView® System, visit
www.spectral-ai.com.
Forward Looking
Statements Certain statements made in this release
are “forward looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities
Litigation Reform Act of 1995, including statements regarding the
Company’s strategy, plans, objectives, initiatives and financial
outlook. When used in this press release, the words “estimates,”
“projected,” “expects,” “anticipates,” “forecasts,” “plans,”
“intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,”
“propose” and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements.
These forward-looking statements are not
guarantees of future performance, conditions or results, and
involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside
Company’s control, that could cause actual results or outcomes to
differ materially from those discussed in the forward-looking
statements. As such, readers are cautioned not to place undue
reliance on any forward-looking statements.
Investors should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” sections of the Company’s filings with the
SEC, including the Registration Statement and the other documents
filed by the Company. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements.
Investors: The Equity
Group Devin Sullivan Managing
Director dsullivan@equityny.com
Conor Rodriguez Analyst crodriguez@equityny.com
Spectral AI (NASDAQ:MDAI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Spectral AI (NASDAQ:MDAI)
Historical Stock Chart
From Dec 2023 to Dec 2024